share_log

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K：重大事件
美股SEC公告 ·  11/08 22:35

Moomoo AI 已提取核心訊息

On November 7, 2024, T2 Biosystems, a company incorporated in Delaware and listed on the Nasdaq Capital Market, received a Nasdaq Staff Deficiency Letter indicating that the company's market value of listed securities had fallen below the required minimum of $35 million for continued listing. This valuation had been below the threshold for 30 consecutive trading days, as per Nasdaq Listing Rule 5550(b)(2). Consequently, the company did not receive a grace period and was instead issued a delisting determination. T2 Biosystems intends to appeal this decision by requesting a hearing and paying the associated non-refundable fee of $20,000. The appeal will stay the delisting process until the Nasdaq Hearings Panel makes a decision. During this period, T2 Biosystems' common stock will remain listed and eligible for trading on Nasdaq. However, there is no guarantee that the Panel will allow the company to continue its listing or that the company will meet the listing criteria within any granted extension period.
On November 7, 2024, T2 Biosystems, a company incorporated in Delaware and listed on the Nasdaq Capital Market, received a Nasdaq Staff Deficiency Letter indicating that the company's market value of listed securities had fallen below the required minimum of $35 million for continued listing. This valuation had been below the threshold for 30 consecutive trading days, as per Nasdaq Listing Rule 5550(b)(2). Consequently, the company did not receive a grace period and was instead issued a delisting determination. T2 Biosystems intends to appeal this decision by requesting a hearing and paying the associated non-refundable fee of $20,000. The appeal will stay the delisting process until the Nasdaq Hearings Panel makes a decision. During this period, T2 Biosystems' common stock will remain listed and eligible for trading on Nasdaq. However, there is no guarantee that the Panel will allow the company to continue its listing or that the company will meet the listing criteria within any granted extension period.
2024年11月7日，總部設在特拉華州並在納斯達克資本市場上市的 t2 biosystems 公司收到一封納斯達克工作人員不足函，表明公司所上市證券的市場價值已低於持續上市所需的最低級別3500萬美元。這個估值已經在30個連續交易日內低於納斯達克上市規則5550(b)(2)要求的水平。因此，公司沒有獲得寬限期，而是收到了除牌決定。t2 biosystems 打算通過請求聽證會並支付相關的不可退還費用20,000美元來上訴這一決定。上訴將暫停除牌程序，直到納斯達克聽證會小組作出決定。在此期間，t2 biosystems 的普通股仍將在納斯達克上市並有資格進行交易。然而，並不能保證聽證會小組會允許公司繼續上市，或者公司會在任何獲得的延期期限內滿足上市標準。
2024年11月7日，總部設在特拉華州並在納斯達克資本市場上市的 t2 biosystems 公司收到一封納斯達克工作人員不足函，表明公司所上市證券的市場價值已低於持續上市所需的最低級別3500萬美元。這個估值已經在30個連續交易日內低於納斯達克上市規則5550(b)(2)要求的水平。因此，公司沒有獲得寬限期，而是收到了除牌決定。t2 biosystems 打算通過請求聽證會並支付相關的不可退還費用20,000美元來上訴這一決定。上訴將暫停除牌程序，直到納斯達克聽證會小組作出決定。在此期間，t2 biosystems 的普通股仍將在納斯達克上市並有資格進行交易。然而，並不能保證聽證會小組會允許公司繼續上市，或者公司會在任何獲得的延期期限內滿足上市標準。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間